The company now anticipates full-year sales growth between 6.5% and 7%, a sharp reduction from the previous guidance of 8.3% to 9.3%. Adjusted earnings per share are now expected to land between $14.80 and $14.90, retreating from the earlier projection of $15.10. Third-quarter profit dropped to $753 million, or $1.96 per share, down from $859 million during the same period last year.
In section Market Quotes
Stryker Trims Full-Year Outlook as Third-Quarter Earnings Miss Targets
Shares of Stryker tumbled 7.6% to $288 in after-hours trading after the medical device manufacturer posted third-quarter profits that failed to satisfy internal benchmarks. The shortfall, compounded by revenue figures lagging behind analyst estimates, forced leadership to revise growth projections downward for the remainder of the fiscal year.
Adjusted per-share earnings reached $3.52, missing the $3.55 consensus estimate tracked by FactSet. While revenue climbed 7.7% to $6.52 billion, it still fell short of the $6.62 billion analysts had projected. Chief Executive Kevin Lobo noted that despite the quarterly miss, the company maintains a positive outlook for the final quarter and expects sustained momentum entering 2027. Segment performance remained mixed, with MedSurg and Neurotechnology sales rising 9.2% compared to a 5.7% increase in Orthopaedics. This development follows a year marked by operational headwinds, including a significant cyberattack earlier in 2024, and aligns with broader sector softness after competitor Boston Scientific also reported results below market expectations.
Comments (0)
No comments yet. Be the first!